EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Impact of Osilodrostat on Health‐Related Quality of Life in Cushing's Disease: Analysis of Patient‐Reported Outcomes From the Phase III LINC 3 and LINC 4 Clinical Trials

John Newell‐Price, Beverly M. K. Biller, Maria Fleseriu, Beatrice Gueron, Grzegorz Binowski, Anna Paćkowska, Mônica R. Gadelha

Clinical Endocrinology · 2026-10 · 105 (4) · 452-463

DOI: 10.1111/cen.70166 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Objective Evaluate the effects of osilodrostat short‐ and long‐term treatment on health‐related quality of life (HRQoL) in Cushing's disease. Design LINC 3 and LINC 4 studies (pooled analysis). Patients 185 patients (mean baseline total scores: Cushing's Quality of Life [CushingQoL], 44.0; Beck Depression Inventory II [BDI‐II], 15.6; EuroQol Five Dimensions Five Levels [EQ‐­5D‐5L], 0.7). Measurements Changes from baseline in CushingQoL, BDI‐­II and EQ‐5D‐5L scores. CushingQoL and EuroQol Five Dimensions Three Levels (EQ‐5D‐3L) scores were assessed in analyses of hypocortisolism‐related adverse events (HAEs). Results Mean CushingQoL score improved (all p < 0.001) by +7.72 (Week [W]12), +11.45 (W26; achieving minimal clinically important difference [MCID]) and +15.32 (W72). Mean BDI‐II score improved (all p < 0.001) by −19.0% (W12; achieving MCID) and −41.2% (W72). EQ‐5D‐5L utility score improved over W26–72 ( p < 0.01), reaching the MCID range at W26. All items/domains in the HRQoL questionnaires significantly improved over time ( p < 0.001; ordinal mixed‐effects regression), except one BDI‐II item (past failure) and one EQ‐5D‐5L domain (self‐care). CushingQoL total score improved in patients with mild (mean urinary free cortisol [mUFC] ≤ 2x upper limit of normal [ULN]), moderate (mUFC > 2–5 × ULN) and severe (mUFC > 5 × ULN) hypercortisolism. BDI‐II and EQ‐5D‐5L total scores improved in patients with moderate and severe hypercortisolism. Grade 3 HAEs temporarily reduced CushingQoL and EQ‐5D‐3L scores during event weeks. In the multivariable models, longer treatment duration was associated with CushingQoL improvements; higher mUFC, higher body mass index, and occurrence of HAEs were associated with lower CushingQoL scores. Conclusions Osilodrostat improved HRQoL, with clinically meaningful, consistent improvements across HRQoL assessments.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →